Inhibition of hepatitis C entry: Too soon to dismiss while many are still being denied treatment by Uprichard, Susan L. & Sainz, Bruno
  
 
 
Repositorio Institucional de la Universidad Autónoma de Madrid 
https://repositorio.uam.es  
Esta es la versión de autor del artículo publicado en: 
This is an author produced version of a paper published in: 
 
       Gut 64.4 (2015): 690-691 
 
DOI:  10.1136/gutjnl-2014-.308396 
Copyright: © 2015, BMJ Publishing Group 
El acceso a la versión del editor puede requerir la suscripción del recurso 
Access to the published version may require subscription 
 
Confidential: For Review Only
 
 
 
 
 
 
Inhibition of Hepatitis C entry: too soon to dismiss while 
many are still being denied treatment 
 
 
Journal: Gut 
Manuscript ID: gutjnl-2014-308396 
Article Type: Commentary 
Date Submitted by the Author: 08-Sep-2014 
Complete List of Authors: Uprichard, Susan; Loyola University Medical Center, Department of 
Medicine 
Sainz, Bruno; Autónoma University of Madrid, Department of Preventative 
Medicine, Public Health and Microbiology 
Keywords: ANTIVIRAL THERAPY, HEPATITIS C 
  
 
 
http://mc.manuscriptcentral.com/gut
Gut
Confidential: For Review Only
Inhibition of Hepatitis C entry: too soon to dismiss while many are still being 
denied treatment  
 
Susan L. Uprichard
1
 and Bruno Sainz Jr.
2
 
 
1
Department of Medicine, Loyola University Medical Center, Maywood, IL 60153 USA 
2
 Department of Preventative Medicine, Public Health and Microbiology, Autónoma University of 
Madrid, Madrid, Spain 
 
Recently in Gut, Xiao et al. detailed an extensive analysis of synergistic inhibition of HCV achieved in 
various in vitro and in vivo models systems when HCV entry inhibitors were combined with different 
direct acting antivirals (DAAs) and host-targeted antiviral (HTAs).
1
  However, a follow-up commentary by 
Pawlotsky suggested that “there is no unmet clinical need” for the treatment of HCV that cannot be 
addressed by the HCV drugs currently approved or in late stage clinical development.
2 
 Here we 
comment on the original study and subsequent commentary. 
 
Consistent with the Xiao et al. study, we have reported that blocking the HCV entry factor Neimann-Pick-
C1-like-1 (NPC1L1) with the FDA-approved drug ezetimibe synergistically inhibits chronic HCV infection 
in vitro when combined with interferon
3
 and, as we present in Figure 1, with HCV DAAs that block 
intracellular viral production. Importantly, we also showed that the synergy achieved was dependent on 
not only blocking cell-free virus entry, but also blocking HCV cell-to-cell spread.
3
  While blocking some 
HCV entry factors potently inhibits HCV cell-to-cell spread (e.g. NPC1L1 , CLDN1, SRB1, EGFR), blocking 
other HCV entry factors (e.g. TfR1 and CD81) has a smaller effect and still allows for substantial cell-to-
cell spread. Relevant to this, we demonstrated that unlike ezetimibe, when an HCV entry inhibitor 
targeting TfR1 was combined with interferon no synergy was observed.
3
 Similarly, in the Xiao et al. 
study,
1
 combinations with anti-CD81 were in most cases the least synergistic/effective and anti-CD81 
was not included at all in the chronic infection inhibition experiments. This is consistent with our 
proposal that the key to achieving synergy between viral entry inhibitors and other antivirals depends on 
whether the “entry inhibitor” also efficiently blocks viral cell-to-cell spread and thus highlights viral cell-
to-cell spread as a previously unrecognized, but critically important antiviral drug target. 
 
While the Pawlostsky commentary is correct that the insights from our and the Xiao et al. studies have 
significant implications for the treatment of other viral infections, it seems premature to assume that 
these findings are too late to be of benefit to those chronically infected with HCV. Two points in 
particular are relevant. First, we know that escape occurs during HCV DAA treatment, but in clinical trials 
the majority of patients clear the infection nonetheless.
2,4
 However, as acknowledged by Pawlotsky, the 
extent of viral resistance that will be encountered in real-life less-compliant populations remains 
unknown. In this regard, HCV entry/spread inhibitors could be beneficial as they increase the kinetics of 
viral decline limiting the time available for escape and also prevent the spread and thus subsequent 
amplification of escape mutants that may arise.  Another issue not yet addressed in this discussion is 
cost. Although new extremely effective antivirals have been and continue to be approved, the 
prohibitive cost of these treatments place them out of reach for the majority of HCV-infected individuals 
with the most recent AASLD guidelines advocating treatment of only the sickest patients.
5
 Yet, the 
synergy data we
3
 (Fig. 1) and Xiao et al.
1
 present, reveal that inexpensive FDA-approved drugs, such as 
ezetimibe, that inhibit HCV entry/ spread may have potential as adjunctive therapy to shorten therapy 
duration or be used in a cocktail in place of a more expensive DAA to help reduce these restrictive costs.  
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Hence, we would argue that considering the current number of patients not being treated, it would be 
hasty to dismiss HCV entry/spread inhibitors as a viable clinical option especially when some inexpensive 
potential candidates are already FDA-approved and have proven safe for human use. 
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Figure Legends 
Figure 1. Synergy between HCV entry/spread inhibitor ezetimibe and direct-acting antivirals. 
Chronically HCV infected Huh7 cells were mock-treated (black) or treated with 30 µM ezetimibe (EZE; grey). (A) 
Parallel cultures were treated with 1µM of the HCV polymerase inhibitor RG7128 alone (RG7128; light blue) or in 
combination 30 µM ezetimibe (RG + EZE; dark blue) (B) Parallel cultures were treated with 200nM of the HCV 
protease inhibitor ITMN5537 alone (ITMN5537; light blue) or in combination 30 µM ezetimibe (ITMN + EZE; dark 
blue).  At 24, 48, and 72 hours post-treatment, intracellular RNA was extracted. HCV and cellular GAPDH RNA 
levels were quantified by RT-qPCR. HCV copies were normalized to cellular GAPDH and are expressed as average 
number of HCV copies/µg RNA in triplicate samples +/- std dev. Significant differences between the DAA treated 
samples and the DAA + EZE treatment are indicated (F-test *P<0.05, **P<0.005). 
 
 
Page 2 of 3
http://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Figure 1. Synergy between HCV entry/spread inhibitor ezetimibe and direct-acting antivirals. Chronically 
HCV infected Huh7 cells were mock-treated (black) or treated with 30 µM ezetimibe (EZE; grey). (A) Parallel 
cultures were treated with 1µM of the HCV polymerase inhibitor RG7128 alone (RG7128; light blue) or in 
combination 30 µM ezetimibe (RG + EZE; dark blue) (B) Parallel cultures were treated with 200nM of the 
HCV protease inhibitor ITMN5537 alone (ITMN5537; light blue) or in combination 30 µM ezetimibe (ITMN + 
EZE; dark blue).  At 24, 48, and 72 hours post-treatment, intracellular RNA was extracted. HCV and cellular 
GAPDH RNA levels were quantified by RT-qPCR. HCV copies were normalized to cellular GAPDH and are 
expressed as average number of HCV copies/µg RNA in triplicate samples +/- std dev. Significant 
differences between the DAA treated samples and the DAA + EZE treatment are indicated (F-test *P<0.05, 
**P<0.005).  
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